Introduction: Neuroendocrine tumors (NETs) with diffuse liver metastases have a poor prognosis and prove difficult to palliate. Somatostatin analogues and chemotherapy have been used but often are poorly tolerated and may not provide symptom relief. Transarterial Embolization (TAE) is being increasingly used to improve symptom control and reduce tumor size. We looked at the last 5-year experience of TAE in patients with hepatic metastases from neuroendocrine tumors.
Aim(s): To investigate outcome of patients treated with TAE in the last five years. To look specifically at objective improvement in symptoms and tumor size, including use or RECIST criteria. To look at long-term survival after TAE.
Materials and methods: From our radiology department, we identified all patients who received TAE within the last five years. We used a pre-developed proforma and obtained data from case notes and e-records for: demographics, type of NET, other treatment received including medical therapy and any surgery. We determined the number of TAE treatments per patient, and determined symptoms before and after TAE. We also looked for radiological and biochemical response. We also looked at survival rates. The mean survival time was defined as from time of TAE to date of death or most recent follow-up - December 2009.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr Dalvinder S Mandair
To read results and conclusion, please login ...
Further abstracts you may be interested in